for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Evotec SE

EVTG.DE

Latest Trade

18.73EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

16.23

 - 

27.29

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
18.73
Open
--
Volume
--
3M AVG Volume
28.82
Today's High
--
Today's Low
--
52 Week High
27.29
52 Week Low
16.23
Shares Out (MIL)
150.33
Market Cap (MIL)
2,794.81
Forward P/E
65.12
Dividend (Yield %)
--

Next Event

Evotec SE at Berenberg 1-1 Symposium at the German Equity Forum

Latest Developments

More

Merck Signs License Agreement With Evotec

Evotec Raises 2019 EBITDA Guidance, Confirms Revenue Outlook

Evotec Announces Partnership With Integra Holdings, Yissum

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Evotec SE

Evotec SE is a Germany-based drug discovery alliance and development partnership company. The Company focuses mainly on product approaches with a number of pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Industry

Biotechnology & Drugs

Contact Info

Essener Bogen 7

+49.40.560810

https://www.evotec.com/

Key Stats

1.63 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.2K

2017

0.3K

2018

0.4K

2019(E)

0.4K
EPS (EUR)

2016

0.200

2017

0.160

2018

0.470

2019(E)

0.285
Price To Earnings (TTM)
44.92
Price To Sales (TTM)
6.55
Price To Book (MRQ)
6.01
Price To Cash Flow (TTM)
27.29
Total Debt To Equity (MRQ)
94.97
LT Debt To Equity (MRQ)
91.57
Return on Investment (TTM)
8.29
Return on Equity (TTM)
6.63

Latest News

Latest News

BRIEF-Evotec And Celgene Enter Into Strategic Oncology Partnership

* DGAP-ADHOC: EVOTEC AND CELGENE ENTER INTO STRATEGIC ONCOLOGY PARTNERSHIP

BRIEF-Evotec Says Endometriosis Programme With Bayer Moves To Phase I Development

* DGAP-NEWS: EVOTEC AND BAYER ADVANCE THIRD ENDOMETRIOSIS PROGRAMME INTO PHASE I CLINICAL DEVELOPMENT Source text for Eikon: Further company coverage:

BRIEF-Evotec AG Says ‍Plans Conversion Into European Company​

* SAYS PLANS CONVERSION INTO EUROPEAN COMPANY Source text for Eikon: Further company coverage: (Reporting by Frankfurt Newsroom)

Sanofi, Evotec team up for research on infectious diseases treatment

Sanofi and Evotec said they had started exclusive talks over accelerating research into the treatment of infectious diseases, and added on Thursday that they would form a new open innovation platform in this area, led by Evotec.

BRIEF-Evotec, Apeiron Biologics receive milestone payment from Sanofi

* SAYS EVOTEC AND APEIRON ACHIEVE FIRST MILESTONE IN IMMUNO-ONCOLOGY ALLIANCE WITH SANOFI

BRIEF-Evotec receives milestone payment from Boehringer Ingelheim​

* SAYS EVOTEC RECEIVES CLINICAL MILESTONE AS PART OF ITS DISCOVERY ALLIANCE WITH BOEHRINGER INGELHEIM

BRIEF-Evotec affirms guidance after 9-month core profit jump

* 9M adjusted group EBITDA up 28% to eur 39.3 m (9m 2016: eur 30.6 m)

BRIEF-Evotec, Tesaro enter partnership on novel immuno-oncology agents

* dgap-news: evotec and tesaro enter strategic partnership to discover novel immuno-oncology agents

BRIEF-Evotec achieves first milestone in neurodegeneration alliance with Celgene​

* Evotec achieves first milestone in neurodegeneration alliance with Celgene

BRIEF-Evotec receives $5 million milestone in Celgene alliance

* Says announced today that its strategic alliance with celgene has reached a first milestone triggering revenues of $ 5.0 m to evotec, which are recognised in q3 of 2017 Source text for Eikon: Further company coverage: (Frankfurt newsroom)

BRIEF-Evotec says invests in Exscientia to advance AI-driven drug discovery

* Says Evotec invests in Exscientia to advance AI-driven drug discovery

BRIEF-Evotec: EIB grants Evotec unsecured loan facility of up to EUR 75 mln

* DGAP-NEWS: EUROPEAN INVESTMENT BANK SUPPORTS EVOTEC'S INNOVATE STRATEGY WITH EUR 75 M LOAN

BRIEF-Abivax and Evotec enter into strategic collaboration

* ABIVAX AND EVOTEC ENTER INTO STRATEGIC COLLABORATION TO DEVELOP NOVEL ANTIVIRAL AGENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Evotec completes acquisition of Aptuit

* Says completes acquisition of aptuit Source text for Eikon: Further company coverage:

BRIEF-Evotec confirms outlook after H1 core profit jump

* Group revenues: 37% increase to eur 103.4 m (h1 2016: eur 75.5 m);

Evotec shares jump as Aptuit deal boosts contract research

Shares in Evotec <EVTG.DE> jumped on Monday after the German biotech firm struck a deal to acquire U.S. company Aptuit for $300 million to expand its outsourced drug discovery and development business.

BRIEF-Germany's Evotec to acquire U.S.-based Aptuit for 256 mln euros

* Evotec to acquire Aptuit, expanding leadership in external innovation

BRIEF-Evotec expands collaboration with Storm Therapeutics

* Says expands collaboration with Storm Therapeutics on its RNA epigenetics platform

BRIEF-Evotec gets milestone payment from Bayer on endometriosis

* Says Evotec and Bayer advance endometriosis programme into phase I clinical development and extend alliance

BRIEF-Evotec receives grant funding from IFB Hamburg

* Says received funding from IFB Hamburg to identify antibody-mediated t-cell immunotherapies Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up